Medical aminoreduction with sulindac to reduce cord complications in monoamniotic twins

Article Abstract:

The drug sulindac may effectively reduce amniotic fluid volume and umbilical cord entanglement in twin pregnancies with a single amniotic sac. Researchers identified three twin pregnancies with a single amniotic sac that were at risk of cord compression and entanglement. Sulindac was given to the mothers twice a day beginning at weeks 27, 29, and 24 of pregnancy. Sulindac achieved a dose-related decrease of amniotic fluid volume and fetal urine production without compromising fetal circulation. All six twins were electively delivered at 32 weeks of pregnancy without complications.

Health aspects, Prevention, Pregnancy, Complications of, Pregnancy complications, Amniotic fluid, Sulindac

---

Prenatal diagnosis by minimally invasive first-trimester transcervical sampling is unreliable

Article Abstract:

Tests on cell samples from the cervix do not appear to be a reliable way to determine the fetus' gender in the first trimester of pregnancy. One of two types of genetic tests, fluorescence in situ hybridization or polymerase chain reaction, was performed on cervical swab samples from 87 women terminating their pregnancy in the first trimester. Fluorescence in situ hybridization tests correctly identified the gender in up to 72% of 36 samples. Polymerase chain reaction tests correctly identified 79% of the male fetuses and 45% of the female fetuses.

Analysis, Evaluation, Fetal tissues, Prenatal diagnosis

---

Similar abstracts:

• Abstracts: The new medical malpractice crisis. Claims, errors, and compensation payments in medical malpractice litigation
• Abstracts: Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review
• Abstracts: Predictors of readmission for complications of coronary artery bypass graft surgery. Long-Term outcomes of coronary-artery bypass grafting versus stent implantation
• Abstracts: Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis
• Abstracts: Medicare's requirement for research participation as a condition of coverage: Is it ethical? The patents-based pharmaceutical development process: Rationale, problems, and potential reforms

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.